This study evaluates the use of oxytocin, given as a nasal spray, for treatment of high frequency episodic migraine and chronic migraine.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
240
Unnamed facility
Fitzroy, Australia
Unnamed facility
Prahran, Australia
Unnamed facility
Sherwood, Australia
Unnamed facility
Santiago, Chile
Unnamed facility
Tauranga, New Zealand
Mean change of migraine days
Baseline is the 28-day screening period before study drug administration
Time frame: Baseline and 28 days of treatment
Mean change of moderate or severe headache days
Time frame: Baseline and 28 days of treatment
Proportion of subjects experiencing a ≥50% reduction in migraine days
Time frame: Baseline and 28 days of treatment
Mean change in days using rescue medication
Time frame: Baseline and 28 days of treatment
Proportion of subjects experiencing a reduction in headache severity and pain score 2 hours after dosing
Time frame: Baseline and 28 days of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Wellington, New Zealand